Leishmaniasis and HIV infection


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper reviews the literature on the problem that becomes increasingly relevant due to the pandemic of HIV infection and the high incidence of leishmaniasis worldwide. At the present time leishmaniasis has become one of the opportunistic infections taking the lives of patients with AIDS in the endemic regions and in some of them visceral leishmaniasis is a main cause of death in the HIV-infected. The steady rise in the HIV epidemic in the Russian Federation, expanding tourist routes, including those to visceral leishmaniasis-endemic regions, and the possible contamination with both infections through parenteral drug use can result in the occurrence of cases of this co-infection in our country. As a reminder about this, the authors give a brief description of the first patient with HIV infection concurrent with visceral leishmaniasis.

Full Text

Restricted Access

About the authors

Tatiana N. Ermak

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: ermak@hivrussia.net

References

  1. World Health Organization. Leishmaniasis and HIV coinfection. http://www.who.int/leishmaniasis/burden/hiv_coinfection/burden_hiv_coinfection/en/index.html. Last accessed December 22, 2008.
  2. Alvar J., Aparicio P., Aseffa A., Den Boer M., Canavate C., Dedet J.P. et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 2008; 21: 334-359.
  3. Andreani G., Lodge R., Richard D., Tremblay M.J. Mechanisms of interaction between protozoan parasites and HIV. Curr. Ophin HIV AIDS2012, 7(3): 276-282.
  4. Борьба с лейшманиозом. Доклад на заседании Комитета экспертов ВОЗ по борьбе с лейшманиозом. Женева, 22-26 марта 2010 г. Серия технических докладов ВОЗ № 949. ВОЗ, 2011. 243 с.
  5. Rabello A., Orsini М., Disch J. Leishmania/HIV co-infection in Brazil: an appraisal. Ann. Trop. Med. Parasitol. 2003; 97(Suppl 1): 17-28.
  6. Cota G.F., de Sousa M.R., Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl. Trop. Dis. 2011; 5: e1153.
  7. World Health Organization. Report of the fifth Consultative Meeting on HIV-Leishmania co-infection. Addis Ababa (Ethiopia); 20-22 March 2007. 32 p.
  8. Epidemiological Analysis of 629 Retrospective Casts of Leishmania/HIV coinfection. Geneva, WHO 1996. 39 p.
  9. Lyons S., Veeken H., Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop. Med. Int. Health 2003; 8: 733-739.
  10. Garg R., Barat C., Ouellet M., Lodge R., Tremblay M.J. Leishmania infantum amastigotes enhance HIV production in cocultures of human dendritic cells and CD4 T cells by inducing secretion of IL-6 and TNF-alpha. PLoS Negl. Trop. Dis. 2009; 3: e441.
  11. Garg R., Lodge R., Descoteaux A., Tremblay M.J. Leishmania infantum promastigotes reduce entry of HIV into macrophages through a lipophosphoglycan-mediated disruption of lipid rafts. J. Infect. Dis. 2008; 197: 1701-1708.
  12. Cruz I., Nieto J., Moreno J., Canavate C., Desjeux P., Alvar J. Leishmania/HIV co-infections in the second decade. Indian J. Med. Res. 2006; 123: 357-388.
  13. Lopez-Velez R., J.A. Perez-Molina A.G., Baquero F., Villarrubia J., Escribano L., Bellas C. et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am. J. Trop. Med. Hyg. 1998; 58: 436-443.
  14. Lyons, S., Veeken H., Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop. Med. Int. Health 2003; 8: 733-739.
  15. Murray H.W. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDs 1999; 13: 459-465.16.
  16. Pintado V., Lopez-Velez R. HIV-associated visceral leishmaniasis. Clin. Microbiol. Infect. 2001; 7: 291-300.
  17. Pintado V., Martin-Rabadan P., Rivera M. L., Moreno S., Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non- HIV-infected patients. A comparative study. Medicine (Baltimore) 2001; 80: 54-73.
  18. Rosenthal E., Marty P., del Giudice P., Pradier C., Ceppi C., Gastaut J.A. et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin. Infect. Dis. 2000; 31: 1093-1095.
  19. Russo R., Laguna F., Lopez-Velez R., Medrano F.J., Rosenthal E., Cacopardo B., Nigro L. Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. Ann. Trop. Med. Parasitol. 2003; 97(Suppl. 1): 99-105.
  20. Alexandrino-de-Oliveira P., Santos-Oliveira J.R., Cavalheiros Dorval M.E. HIV/AIDS-assotiated visceral leishmaniasis in patients from an endemic area in Centralwest Brazil. Memorias do Instituto Osvaldo Crus 2010; 105(5): 692-697.
  21. Ritmeijer K., Veeken H., Melaku Y., Leal G., Amsalu R., Seaman J. et al. Davidson R.N. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans. R. Soc. Trop. Med. Hyg. 2001; 95: 668-672.
  22. Ritmeijer K., Dejenie A., Assefa Y., Hundie T.B., Mesure J., Boots G. et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin. Infect. Dis. 2006; 43: 357-364.
  23. Fernandez Cotarelo M.J., Abellan Martinez J., Guerra Vales J.M., Martinez Sanchez P., Rodrigo Gomez De La Barcena M., Salto Fernandez E. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 2003; 37: 973-977.
  24. Delgado J., Macias J., Pineda J.A., Corzo J.E., GonzalezMoreno M.P., de la Rosa R. et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am. J. Trop. Med. Hyg. 1999; 61: 766-769.
  25. Barat C., Zhao C., Ouellette M., Tremblay M.J. HIV-1 replication is stimulated by sodium stibogluconate, the therapeutic mainstay in the treatment of leishmaniasis. J. Infect. Dis. 2007; 195: 236-245.
  26. Lopez-Velez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann. Trop. Med. Parasitol. 2003; 97(Suppl. 1): 143-147.
  27. Casado J.L., Lopez-Velez R., Pintado V., Quereda C., Antela A., Moreno S. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur. J. Clin. Microbiol. Infect. Dis. 2001; 20: 202-205.
  28. Villanueva J.L., Alarcon A., Bernabeu-Wittel M., Cordero E., Prados D., Regordan C. et al. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis. 2000; 19: 798-801.
  29. Mira J. A., Corzo J.E., Rivero A., Macias J., De Leon F.L., Torre-Cisneros J. et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am. J. Trop. Med. Hyg. 2004; 70: 298-301.
  30. de La Rosa R., Pineda J.A., Delgado J., Macias J., MorillasF., Mira J. et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J. Clin. Microbiol. 2002; 40: 762-767.
  31. WHO. Report on the consultative meeting on Leishmania/HIV co-infection. WHO/LEISH/95.35. Rome (Italy), 6-7 September, 1994. 15 p.
  32. Константинова Т.Н., Лысенко А.Я., Лавдовская М.В., Имамкулиев К.Д., Селькова Е.П., Анчукова Э.Л. и др. Случай микст-инфекции: висцеральный лейшманиоз ВИЧ у жителя России. Сб. науч. тр. «Актуальные вопросы эпидемиологии инфекционных болезней» 1997; вып. 2: 332-335.
  33. Ермак Т.Н., Кравченко А.В., Груздев Б.М., Филиппов П.Г. Первый случай висцерального лейшманиоза у больного с ВИЧ-инфекцией в России. Тер. архив 1997; 11: 48-50.
  34. Чемич М.Д., Троцька І.О., Кулеш Л.П. та ін. Вісцеральний лейшманіоз як СНІД-індикаторне захворювання: труднощі в діагностиці та лікуванні. Інфекційні хвороби 2010; 1: 81-84.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies